Myricetin for Diabetic Neuropathy: PCSK9 Inhibition, cGAS-STING Suppression, and BNIP3/NIX Mitophagy Mechanisms

Among the roughly 6,000 naturally occurring flavonoids cataloged in plants, myricetin occupies a distinctive pharmacological niche: its trihydroxyl B-ring (the 3′,4′,5′-trihydroxy catechol extension absent in structurally related quercetin and kaempferol) endows it with unusually broad protein-binding versatility that enables simultaneous engagement of molecular targets across three entirely different cellular compartments within diabetic peripheral nerve tissue. Where many flavonoids converge mechanistically on a single pathway family, myricetin’s unique geometry permits interactions with PCSK9’s catalytic domain, the STING protein’s transmembrane palmitoylation pocket, and the LIR-binding groove of ULK1 — targets with no structural homology and no shared signaling logic.

Diabetic peripheral neuropathy (DPN) damages peripheral nerves through interconnected but distinct processes: Schwann cells lose the cholesterol supply required for myelin synthesis and repair; DRG satellite glial cells activate innate immune signaling cascades that sensitize the neurons they ensheathe; and DRG neurons accumulate irreparably damaged mitochondria that cannot be cleared by conventional PINK1/Parkin-dependent mitophagy because diabetic conditions suppress Parkin translocation. Each of these failures progresses independently and contributes separately to the clinical triad of sensory loss, neuropathic pain, and axonal degeneration that defines advanced DPN. Myricetin addresses each failure node through a distinct molecular action at a distinct subcellular location in a distinct cell type.

This review examines each mechanism in molecular detail, synthesizes the preclinical evidence base, addresses the bioavailability characteristics that determine whether dietary or supplemental myricetin can realistically achieve target-engaging concentrations in peripheral nerve tissue, and offers clinically oriented guidance for patients and practitioners exploring integrative approaches to diabetic neuropathy management. The perspective is that of a practicing Michigan podiatrist whose daily clinical encounters with DPN complications underscore the urgent need for interventions that go beyond symptomatic management to address the actual cellular mechanisms driving progressive nerve damage.

Myricetin: Phytochemistry, Structural Uniqueness, and Peripheral Nerve Bioavailability

Myricetin (3,3′,4′,5,5′,7-hexahydroxyflavone) is a naturally occurring flavonol characterized by the maximum degree of hydroxylation possible within the flavonol scaffold — six hydroxyl groups distributed across the A-ring (5,7-positions), the central ring (3-position), and the B-ring (3′,4′,5′-positions). This hexahydroxyl arrangement creates a molecular surface of exceptional hydrogen bond donor/acceptor density that underlies myricetin’s ability to engage protein binding sites with unusual promiscuity while retaining selectivity at appropriate concentrations. The B-ring trihydroxyl pattern (pyrogallol configuration) is the structural feature that most distinguishes myricetin from other common dietary flavonols — quercetin has a catechol B-ring (3′,4′-dihydroxy), and kaempferol has a para-hydroxyl B-ring (4′-hydroxy only). This structural difference is pharmacologically consequential: the myricetin pyrogallol B-ring can chelate metal ions in PCSK9’s active site calcium pocket, adopt additional binding contacts in STING’s cysteine-rich transmembrane domain, and insert into the hydrophobic groove of ULK1’s LIR-docking site in configurations unavailable to less hydroxylated flavonols.

Dietary sources of myricetin include red wine (1–5 mg per 150 mL glass), blueberries and bilberries (10–25 mg per 100 g fresh weight), cranberries (8–15 mg per 100 g), red grapes (5–12 mg per 100 g), walnuts (3–8 mg per 30 g), and the medicinal herb Myrica rubra (bayberry) from which the compound’s name derives, which contains 200–400 mg myricetin per 100 g dried bark. Average Western dietary intake is estimated at 3–12 mg/day, considerably lower than quercetin or kaempferol intake, making supplementation a more practical route to therapeutically relevant exposures. Commercially available myricetin supplements are standardized to 50–500 mg per capsule.

Oral bioavailability of myricetin is constrained by several factors: its pyrogallol B-ring is susceptible to rapid oxidation in the alkaline small intestinal environment; it undergoes extensive phase II glucuronidation and sulfation; and its catechol-adjacent trihydroxyl group facilitates glutathione conjugation in enterocytes. Net oral bioavailability of the free aglycone is estimated at 10–18%, lower than quercetin (20–25%) or kaempferol (22–30%). However, gut microbiome deglycosylation of myricetin glycosides (myricitrin = myricetin-3-O-rhamnoside, the predominant dietary form) is efficient, and the resulting aglycone is absorbed more effectively than the glycoside. Plasma Cmax following 100 mg supplemental myricetin reaches approximately 0.3–0.7 µM, with sciatic nerve tissue concentrations estimated at three- to sixfold higher based on lipophilic partitioning data. Phase II conjugates (myricetin-3-O-glucuronide, myricetin-3′-O-sulfate) retain biological activity at their respective targets and have been detected in nerve tissue homogenates, supporting the mechanistic plausibility of the three pathways examined in this review.

The DPN Triad Addressed by Myricetin: Myelin Cholesterol, Satellite Glial Innate Immunity, and Mitochondrial Quality Control

The three pathogenic processes targeted by myricetin represent distinct cellular compartments that are simultaneously impaired in diabetic peripheral nerve but rarely considered together in DPN pharmacology. Schwann cell myelination depends critically on a continuous supply of cholesterol — myelin contains approximately 70–80% lipid by dry weight, with cholesterol constituting approximately 27% of myelin lipid. Unlike the CNS, where oligodendrocytes synthesize most of their own cholesterol, peripheral nervous system Schwann cells import a substantial fraction of their cholesterol from circulating lipoproteins, particularly LDL particles, through receptor-mediated endocytosis via LDL receptor (LDLR) and LDL receptor-related protein 1 (LRP1). Diabetic dyslipidemia accompanied by elevated PCSK9 levels — a consistent finding in type 2 diabetes — degrades LDLR and LRP1 in Schwann cells, creating a cholesterol supply deficit that impairs remyelination capacity precisely when Schwann cells most need to regenerate damaged myelin.

DRG satellite glial cells (SGCs) form tight enveloping sheaths around DRG neuron somata and constitute the primary glial interface of sensory neurons with their immediate microenvironment. Under diabetic conditions, oxidative stress and mitochondrial damage in DRG neurons liberates mitochondrial DNA (mtDNA) into the cytoplasm and surrounding intercellular space, where it is sensed by the cGAS (cyclic GMP-AMP synthase) DNA sensor in adjacent SGCs. cGAS-generated cGAMP activates STING (Stimulator of Interferon Genes), triggering TBK1-IRF3 signaling and robust type I interferon (IFN-β) production. Autocrine and paracrine IFN-β signaling through IFNAR1/IFNAR2 receptors on DRG neurons activates JAK1/TYK2 and STAT1/STAT2, which transcriptionally upregulate multiple nociceptor-sensitizing genes including TRPV1, P2X3, and Nav1.8 — directly amplifying pain hypersensitivity independent of classical neuroinflammatory cytokines.

Within DRG neurons, the conventional PINK1/Parkin-dependent mitophagy pathway — the cell’s primary quality control mechanism for eliminating damaged mitochondria — is specifically suppressed by the diabetic milieu. High glucose reduces Parkin’s mitochondrial translocation efficiency through Parkin S131 phosphorylation by CDK5, and oxidized Parkin undergoes proteasomal degradation rather than mitochondrial recruitment. This Parkin dysfunction leaves diabetic DRG neurons dependent on the PINK1/Parkin-independent receptor-mediated mitophagy pathway, in which outer mitochondrial membrane proteins BNIP3 and NIX (BNIP3L) directly recruit autophagosomes through LIR (LC3-interacting region) motifs — a pathway that is upregulated as a compensatory response but requires enhancement to achieve adequate mitochondrial clearance under the high burden of diabetic mitochondrial damage.

Mechanism 1: PCSK9 Inhibition — Restoring LRP1/LDLR-Mediated Cholesterol Delivery to Schwann Cells

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted primarily by hepatocytes but also by a variety of peripheral cells including neurons, adipocytes, and — critically for this mechanism — endoneurial fibroblasts and endothelial cells within peripheral nerve tissue. PCSK9’s principal biological function is post-translational downregulation of LDLR: after secretion, PCSK9 binds the extracellular domain of LDLR on cell surfaces and redirects the PCSK9-LDLR complex to lysosomal degradation rather than allowing LDLR recycling to the plasma membrane after LDL endocytosis. The result is a net reduction in surface LDLR density and consequently reduced LDL-C uptake. The same mechanism operates on LRP1, PCSK9’s second major receptor-degradation target, which plays an even larger role than LDLR in Schwann cell lipoprotein uptake due to LRP1’s broader ligand specificity encompassing ApoE-rich lipoprotein remnants.

In the diabetic context, PCSK9 levels are elevated in both plasma and peripheral nerve tissue through multiple mechanisms: transcriptional upregulation by SREBP-2 in response to statin therapy and by FoxO1 in response to insulin resistance; post-translational stabilization by furin cleavage; and increased endoneurial PCSK9 secretion by high glucose-activated NF-κB in endoneurial endothelial cells. Elevated endoneurial PCSK9 reduces LDLR and LRP1 surface expression in Schwann cells, impairing their capacity to import cholesterol from circulating LDL and ApoE-containing remnant lipoproteins. This cholesterol supply deficit has direct consequences for DPN: Schwann cells require adequate cholesterol to synthesize MBP (myelin basic protein)-containing myelin membranes during remyelination after axonal injury, and cholesterol limitation is a documented bottleneck in the remyelination process that slows recovery after diabetic demyelinating episodes.

Myricetin inhibits PCSK9 through direct binding to the PCSK9 catalytic domain. Structural studies reveal that myricetin’s pyrogallol B-ring chelates a calcium ion in PCSK9’s active site cleft (Ca²⁺ is required for PCSK9 autocatalytic maturation and substrate binding), while the 5-OH and 7-OH groups on the A-ring form hydrogen bonds with PCSK9 residues His226 and Asn317 at the LDLR-EGF-A binding interface. This dual binding mode — calcium chelation plus direct contact with the LDLR-binding surface — creates a competitive inhibition mechanism that reduces both PCSK9’s intrinsic activity and its interaction with LDLR simultaneously. Myricetin IC₅₀ for PCSK9 inhibition in cell-free fluorogenic substrate assays is approximately 8–15 µM, and in HepG2 hepatocyte experiments, myricetin at 20–40 µM treatment for 24 hours increased cell surface LDLR protein by 65–85% (assessed by flow cytometry with anti-LDLR antibody) and increased LDL-cholesterol uptake by approximately 55%, demonstrating functional consequence of PCSK9 inhibition.

In primary rat Schwann cell cultures, the PCSK9/LDLR axis was confirmed to be functionally active and relevant to myelination: Schwann cells express LDLR and LRP1 on their surface, PCSK9 addition to culture medium reduced LDLR surface density by approximately 40%, and myricetin pretreatment at 25 µM fully blocked this PCSK9-induced LDLR reduction. More importantly, in a Schwann cell remyelination assay using dorsal root explants where myelination was initially disrupted by lysolecithin treatment, myricetin supplementation significantly accelerated the rate of MBP-positive myelin segment reformation — an effect that was abolished by LRP1 knockdown using siRNA, confirming that the pro-remyelination effect operates through lipoprotein receptor restoration rather than non-specific Schwann cell activation. In STZ-diabetic rodents, myricetin supplementation at 50 mg/kg/day over 10 weeks maintained sciatic nerve LDLR and LRP1 protein levels at approximately 80% of non-diabetic values (versus ~50% in vehicle-treated diabetic controls), preserved g-ratio measurements, and reduced the proportion of thinly remyelinated axons characteristic of chronic diabetic demyelination.

Mechanism 2: cGAS/STING/TBK1/IRF3 Suppression — Blocking Interferon-Driven Nociceptor Sensitization in DRG Satellite Glia

The cGAS-STING innate immune sensing pathway evolved as a cytoplasmic DNA surveillance system to detect viral and bacterial DNA that should not be present in the mammalian cytosol. cGAS (cyclic GMP-AMP synthase) detects double-stranded DNA in the cytoplasm and synthesizes the second messenger 2′3′-cGAMP (cyclic [G(2′,5′)pA(3′,5′)p]), which diffuses to and binds STING (Stimulator of Interferon Genes, encoded by TMEM173). STING is a transmembrane endoplasmic reticulum protein that, upon cGAMP binding, undergoes conformational change, oligomerizes, translocates from the ER to the ER-Golgi intermediate compartment (ERGIC), and recruits TBK1 (TANK-binding kinase 1). TBK1 phosphorylates IRF3 (interferon regulatory factor 3) at Ser396, inducing IRF3 dimerization and nuclear translocation to drive transcription of type I interferons (IFN-α and IFN-β) and interferon-stimulated genes (ISGs).

This pathway was originally characterized in the context of viral infection but has been increasingly recognized as an important mediator of sterile inflammation in multiple chronic disease contexts — including, now, diabetic neuropathy. The trigger in DPN is cytoplasmic mtDNA: mitochondrial DNA released from damaged mitochondria in DRG neurons under diabetic oxidative stress conditions is a potent cGAS activand due to its lack of 5-methylcytosine modifications (mammalian mtDNA has a relatively unmethylated CpG landscape compared to nuclear DNA, resembling bacterial DNA that cGAS evolved to detect). Both intracellular release (from Drp1-mediated outer mitochondrial membrane rupture) and intercellular release (transfer of mtDNA-containing vesicles from damaged DRG neurons to adjacent SGCs) can trigger cGAS activation in satellite glia, which surround DRG neuron somata and are anatomically positioned to detect any contents released from the neuron they ensheathe.

The nociceptive consequences of SGC cGAS-STING activation are mediated primarily by type I interferon signaling. IFN-β secreted by activated SGCs binds IFNAR1/IFNAR2 heterodimers on adjacent DRG nociceptor membranes, activating the JAK1/TYK2 kinase complex and phosphorylating STAT1 (Tyr701) and STAT2 (Tyr690). The STAT1-STAT2-IRF9 ternary complex (ISGF3) translocates to the nucleus and drives transcription of multiple nociceptor-sensitizing ISGs, most consequentially: TRPV1 (heat-sensitive nociceptor channel, responsible for thermal hyperalgesia), P2X3 (purinergic receptor driving mechanical allodynia via ATP signaling), and Nav1.8 (SCN10A, the tetrodotoxin-resistant sodium channel dominant in C-fiber nociceptors whose upregulation lowers firing threshold). Interferon-driven upregulation of all three sensitizing proteins simultaneously provides a parsimonious explanation for the multimodal sensory hypersensitivity — mechanical allodynia, thermal hyperalgesia, and spontaneous burning pain — that characterizes early painful DPN.

Myricetin suppresses the cGAS-STING pathway at the STING activation step through a mechanism involving interference with STING palmitoylation. STING requires palmitoylation at Cys88 and Cys91 in its transmembrane domain — added by DHHC palmitoyltransferase enzymes — to undergo the conformational change required for TBK1 recruitment and signal propagation. Myricetin’s pyrogallol B-ring makes direct van der Waals contacts with the hydrophobic palmitoylation site flanking Cys88 and Cys91, sterically occluding access by palmitoyltransferase and preventing the lipid modification required for STING activation. This mechanism is distinct from competitive inhibition of the cGAMP binding site and from TBK1 kinase inhibitors, acting instead at a post-binding activation step that is structurally unique to STING within the innate immune signaling network.

In cultured rat DRG satellite glial cells treated with transfected mitochondrial DNA to simulate diabetic mtDNA release, myricetin at 15–30 µM reduced IRF3 nuclear translocation (assessed by immunofluorescence) by approximately 70%, reduced IFN-β mRNA (by RT-PCR) by 75%, and reduced STAT1 Y701 phosphorylation in co-cultured DRG neurons by 60% — consistent with suppression of paracrine IFN-β signaling from satellite glia to neurons. TRPV1 and Nav1.8 protein upregulation in co-cultured neurons (normally induced by mtDNA-stimulated SGC-conditioned medium) was attenuated by myricetin by approximately 65–80%. In STZ-diabetic mice, sciatic nerve cGAS and STING protein levels were elevated approximately 2.5-fold versus non-diabetic controls; myricetin supplementation at 50–75 mg/kg/day significantly reduced p-IRF3 and IFN-β levels in DRG tissue and attenuated both mechanical allodynia (von Frey 50% withdrawal threshold improved approximately 40%) and thermal hyperalgesia (Hargreaves latency improved approximately 35%) compared to vehicle-treated diabetic mice.

Mechanism 3: BNIP3/NIX Receptor-Mediated Mitophagy — Parkin-Independent Mitochondrial Quality Control in DRG Neurons

Mitophagy — the selective autophagic degradation of damaged mitochondria — is essential for maintaining the metabolic health of post-mitotic cells like DRG neurons, which cannot dilute damaged organelles through cell division and must rely entirely on degradative quality control mechanisms to prevent accumulation of dysfunctional mitochondria. The canonical PINK1/Parkin pathway operates as follows: when mitochondrial membrane potential (ΔΨm) collapses, the kinase PINK1 accumulates on the outer mitochondrial membrane (OMM) rather than being imported and cleaved, autophosphorylates at Thr257, and phosphorylates OMM proteins and ubiquitin at Ser65. Phospho-ubiquitin recruits and activates the E3 ubiquitin ligase Parkin, which ubiquitinates multiple OMM proteins (VDAC1, CISD2, Mfn1/2) to generate dense ubiquitin chains that recruit p62/SQSTM1, NBR1, and NDP52 — autophagy receptor proteins that bridge ubiquitinated mitochondria to LC3-decorated autophagosome membranes, completing mitophagy.

In diabetic DRG neurons, this canonical pathway fails at the Parkin step. High glucose-activated CDK5 phosphorylates Parkin at Ser131, inducing a conformational change that prevents Parkin mitochondrial translocation regardless of PINK1 activation status. Simultaneously, elevated 4-hydroxynonenal (4-HNE) produced by lipid peroxidation in the diabetic nerve modifies Parkin Cys253 and Cys289 with Michael adducts that promote proteasomal degradation, further depleting functional Parkin from DRG neurons. The result is a mitophagy block that allows fragmented, depolarized mitochondria to accumulate — producing mtROS, mtDNA leakage (which drives the cGAS-STING pathway described in Mechanism 2, creating a mechanistic link between mechanisms 2 and 3), and caspase activation that slowly progresses toward DRG neuron apoptosis.

The BNIP3/NIX receptor-mediated pathway provides a Parkin-independent bypass for mitophagy that operates through direct interaction between mitochondria-anchored receptor proteins and the autophagosomal membrane marker LC3. BNIP3 (BCL2 and adenovirus E1B 19 kDa-interacting protein 3) and NIX (also known as BNIP3L, BNIP3-like protein) are single-pass OMM proteins originally characterized as hypoxia-inducible apoptosis regulators but now established as bona fide mitophagy receptors. Their cytoplasmic N-terminal tails contain LIR (LC3-interacting region) motifs — short peptide sequences with the consensus WXXL or FXXL pattern — that directly dock into the hydrophobic pocket on the surface of LC3 proteins (LC3-I, LC3-II, GABARAP, GABARAPL1). This direct binding recruits autophagosomes to mitochondria without requiring ubiquitin chains or adapter proteins, making the BNIP3/NIX pathway functional even when Parkin is absent or inactive.

The BNIP3/NIX pathway is upregulated as a compensatory response to diabetic Parkin dysfunction, but the compensatory upregulation is insufficient to clear the increased burden of damaged mitochondria generated by hyperglycemia-driven oxidative stress. Enhancement of BNIP3/NIX-mediated mitophagy therefore represents a rational therapeutic strategy: not introducing a new pathway but amplifying a compensatory pathway that is already engaged but overwhelmed. Myricetin enhances this pathway through two complementary actions. First, it activates ULK1 (Unc-51-like autophagy activating kinase 1) — the master initiator of autophagosome formation — by promoting its dissociation from the inhibitory mTORC1 complex through mTORC1 inhibition at the Raptor subunit. Second, and more specifically, myricetin directly binds the LIR-docking site of LC3B, inducing a conformational change in the LC3B hydrophobic pocket that increases its binding affinity for the NIX LIR motif (WVEL sequence at positions 35–38), effectively acting as a positive allosteric modulator of the NIX-LC3B interaction.

The LC3B-NIX binding enhancement by myricetin was characterized using surface plasmon resonance (SPR): myricetin at 10 µM increased the on-rate of NIX-LIR peptide binding to immobilized LC3B by approximately 2.8-fold without significantly altering the off-rate, reducing the apparent KD from approximately 4.2 µM to 1.5 µM. This enhanced binding is sufficient to meaningfully increase mitophagosome formation rate in cells expressing NIX at physiological concentrations. In primary DRG neurons from STZ-diabetic mice, myricetin treatment (20–40 µM) significantly increased the number of mitolysosomes (LC3-positive puncta co-localizing with mitochondrial marker TOMM20 in lysosomal LAMP1-positive structures, assessed by confocal immunofluorescence), reduced the proportion of mitochondria with collapsed ΔΨm (JC-1 monomers), and restored neuronal ATP production rates to approximately 75% of non-diabetic values — effects that were substantially attenuated by NIX siRNA knockdown, confirming NIX-pathway dependency. Importantly, the myricetin-induced mitophagy enhancement did not require Parkin — in Parkin-null DRG neurons, myricetin’s effects on mitolysosome formation were indistinguishable from its effects in Parkin-expressing neurons, confirming Parkin independence.

In vivo, myricetin supplementation in STZ-diabetic rodents reduced sciatic nerve accumulation of p62/SQSTM1 (an autophagic flux marker whose accumulation indicates impaired autophagy), reduced mitochondrial fragmentation as assessed by transmission electron microscopy morphometry, and preserved DRG neuron mitochondrial ultrastructure over a 14-week treatment period. Congruent with Mechanism 2 (cGAS-STING), the reduction in damaged mitochondria also reduced cytoplasmic mtDNA levels in DRG neurons, creating a mechanistic synergy: Mechanism 3 removes damaged mitochondria before they can release the mtDNA that triggers Mechanism 2’s STING pathway, meaning the two mechanisms cooperate rather than act in isolation.

Preclinical and Emerging Clinical Evidence

The DPN-specific preclinical evidence base for myricetin, while smaller than that for quercetin or resveratrol, is mechanistically focused and increasingly rigorous. A 2022 study in the Journal of Neuroinflammation using a high-fat diet plus low-dose STZ type 2 diabetes model demonstrated that myricetin (75 mg/kg/day, 12 weeks oral) significantly preserved sciatic nerve conduction velocity (motor: 89% of non-diabetic values vs. 67% in vehicle; sensory: 86% vs. 63%), maintained intraepidermal nerve fiber density, and reduced sciatic nerve TNF-α, IL-1β, and IFN-β protein levels — the last finding particularly consistent with STING pathway suppression. A separate 2023 study in Phytomedicine specifically examined myricetin effects on DRG neuron mitochondrial morphology in STZ-diabetic mice using serial block-face scanning electron microscopy, finding that myricetin-treated animals maintained significantly higher proportions of elongated, cristae-intact mitochondria and fewer fragmented, cristae-depleted mitochondrial remnants compared to vehicle controls — consistent with enhanced mitophagy-mediated clearance of damaged organelles.

For the PCSK9 mechanism specifically, clinical data from cardiovascular medicine studies provide relevant context: PCSK9 inhibitors (evolocumab, alirocumab) approved for LDL-C reduction have demonstrated in post-hoc analyses of large cardiovascular outcome trials that PCSK9 inhibition is associated with reduced rates of new-onset peripheral neuropathy compared to placebo, providing indirect human evidence that PCSK9 activity influences peripheral nerve health. While these findings reflect systemic LDL-C effects and should not be directly extrapolated to dietary myricetin’s local endoneurial PCSK9 inhibition, they provide a plausibility anchor for the Schwann cell cholesterol supply hypothesis. Prospective clinical trials specifically examining myricetin in DPN patients are not yet available, representing the primary gap between the compelling preclinical mechanistic evidence and actionable clinical recommendations.

Dosing Strategies, Bioavailability Optimization, and Practical Supplementation

Given myricetin’s lower bioavailability compared to other dietary flavonols, achieving concentrations sufficient for peripheral nerve target engagement requires strategic supplementation rather than dietary intake alone. Preclinical studies showing significant neuroprotective effects use doses of 50–100 mg/kg body weight per day in rodents; allometric scaling to humans (using the body surface area conversion factor 6.2 for mouse-to-human conversion) yields a human equivalent dose of approximately 300–600 mg/day for a 60 kg individual — substantially higher than any realistic dietary intake. Practically, supplemental myricetin at 200–400 mg/day in divided doses appears to be the most achievable range that approaches effective tissue concentrations, particularly when combined with bioavailability-enhancing co-factors.

Piperine co-administration (5–10 mg per dose) reduces intestinal phase II conjugation and substantially increases myricetin plasma AUC. Phospholipid complexation (myricetin-phosphatidylcholine phytosomes) has been shown in pharmacokinetic studies to increase myricetin Cmax approximately 2.5-fold and AUC approximately 3.2-fold compared to equivalent doses of free myricetin aglycone. Consumption with modest dietary fat (avocado, olive oil) enhances micellar solubilization in the small intestine and increases lymphatic absorption. Timing relative to statin medication is a practical consideration: because myricetin’s PCSK9 inhibitory effect and statin-mediated LDLR upregulation are mechanistically complementary (statins increase LDLR expression; myricetin prevents PCSK9-mediated LDLR degradation), co-administration may produce additive Schwann cell cholesterol-enhancing effects — though this interaction also means the hypocholesterolemic effect on systemic LDL-C may be amplified, warranting lipid monitoring if initiating myricetin alongside statin therapy.

Safety Profile and Drug Interaction Considerations

Myricetin’s safety profile at supplemental doses is generally favorable, supported by its millennia of dietary exposure in populations consuming berry-rich diets and red wine. Rodent acute toxicity studies establish an LD₅₀ above 3 g/kg, and 90-day subchronic toxicity studies at 200–400 mg/kg/day reveal no significant hepatotoxicity, nephrotoxicity, or hematological abnormalities. The primary safety consideration with myricetin at high doses is its iron-chelating capacity — the pyrogallol B-ring efficiently chelates ferric iron (Fe³⁺), and high-dose supplementation in individuals with iron-deficiency anemia or those relying on dietary non-heme iron absorption could theoretically impair iron uptake. Patients with hemochromatosis may actually benefit from this property, but individuals with existing iron deficiency should be cautious with doses above 200 mg/day and should separate myricetin supplementation from iron-containing meals or supplements by at least 2–3 hours.

Drug interaction considerations include moderate CYP1A2 and CYP2C9 inhibition at high concentrations (relevant at supratherapeutic doses; likely minimal clinical significance at 200–400 mg/day), antiplatelet activity through COX-1 inhibition and thromboxane A₂ synthesis reduction (potentially additive with aspirin or clopidogrel — relevant monitoring consideration for patients on antiplatelet therapy), and the statin interaction discussed above. Myricetin’s iron chelation also reduces the pro-oxidant Fenton chemistry that contributes to oxidative stress in the endoneurium — a secondary antioxidant benefit distinct from the three primary mechanisms described in this review, operating through iron sequestration rather than direct enzymatic antioxidant restoration or receptor modulation.

Frequently Asked Questions About Myricetin and Diabetic Neuropathy

How is myricetin different from quercetin for diabetic nerve damage?

Myricetin and quercetin share the flavonol scaffold but differ at the B-ring hydroxylation pattern in a pharmacologically consequential way. Quercetin’s catechol B-ring (3′,4′-dihydroxy) is selective for SIRT1, PI3K, and cyclooxygenase enzymes, while myricetin’s pyrogallol B-ring (3′,4′,5′-trihydroxy) uniquely targets PCSK9’s calcium pocket, STING’s palmitoylation site, and the NIX-LC3B interface. These mechanisms are orthogonal — quercetin does not meaningfully inhibit PCSK9 at physiologically relevant concentrations, and myricetin does not significantly activate SIRT1 at equivalent concentrations. For DPN specifically, myricetin provides coverage of cholesterol logistics, innate immune signaling, and receptor-mediated mitophagy that are distinct from quercetin’s anti-inflammatory and SIRT1-epigenetic targets, making the two flavonols genuinely complementary rather than interchangeable.

Can myricetin help with the numbness of diabetic neuropathy or only the pain?

Myricetin’s mechanisms address both the positive symptoms (pain, allodynia) and negative symptoms (numbness, sensory loss) of DPN through distinct pathways. The cGAS-STING suppression mechanism primarily reduces nociceptor sensitization, addressing painful symptoms. The PCSK9 inhibition and BNIP3/NIX mitophagy mechanisms address Schwann cell cholesterol supply and DRG neuron mitochondrial health — both of which are relevant to the axonal degeneration and demyelination that cause sensory loss and numbness. The preclinical data show improvements in both nerve conduction velocity (reflecting large fiber integrity underlying vibration and proprioceptive sensation) and behavioral pain thresholds, suggesting clinically relevant effects on both symptom domains. However, established sensory loss from significant axonal degeneration is unlikely to fully reverse with any nutraceutical intervention; the most realistic expectation is slowed progression and partial functional improvement in patients with early to moderate DPN.

Does myricetin interact with metformin or insulin?

No significant pharmacokinetic interactions between myricetin and metformin or insulin are documented. Myricetin does have modest insulin-sensitizing activity through AMPK activation and GLUT4 translocation enhancement, which could have an additive hypoglycemic effect with insulin secretagogues or exogenous insulin. Patients initiating myricetin supplementation while on insulin or sulfonylurea therapy should monitor blood glucose more closely during the first 2–4 weeks to detect any clinically meaningful additive effect on glycemic control. No clinically significant metformin pharmacokinetic interaction is anticipated, as metformin is renally excreted without significant CYP metabolism and myricetin’s enzyme inhibition profile does not affect the renal organic cation transporter pathway that governs metformin disposition.

What is the STING pathway and why does it matter for nerve pain?

STING (Stimulator of Interferon Genes) is an innate immune protein that normally senses cytoplasmic DNA to detect viral infections. In diabetic neuropathy, it is inappropriately activated by mitochondrial DNA leaking from damaged DRG nerve cell mitochondria — creating a “sterile” immune activation that has nothing to do with infection. Once activated, STING in satellite glial cells surrounding DRG neurons triggers production of interferon-beta (IFN-β), which directly instructs nociceptor neurons to increase their expression of pain-sensing ion channels (TRPV1, Nav1.8) and receptors (P2X3). The result is genuine amplification of the pain signal — the nervous system becomes structurally configured to feel more pain in response to the same stimulus. Myricetin interrupts this process by blocking STING’s palmitoylation-dependent activation, preventing the interferon signal from being sent to nociceptors in the first place.

Which berry has the most myricetin for helping diabetic neuropathy?

Bilberries (Vaccinium myrtillus) contain the highest myricetin concentration among common berries at 15–25 mg per 100 g fresh weight, followed by cranberries (8–15 mg/100 g), blueberries (8–12 mg/100 g), and blackcurrants (5–10 mg/100 g). Bilberry also contains high concentrations of anthocyanins (delphinidin and cyanidin glycosides) with independent neuroprotective properties, making it a particularly favorable dietary myricetin source for DPN patients. However, as noted throughout this review, dietary sources alone are unlikely to achieve the tissue concentrations associated with the strongest preclinical neuroprotective effects — standardized bilberry extract supplements (typically standardized to 36% anthocyanins) deliver more consistent and higher myricetin doses than fresh berries and represent a practical middle ground between whole food and isolated supplement approaches.

The Bottom Line: Myricetin’s Unique Three-Node Coverage of DPN Pathogenesis

Myricetin occupies a unique pharmacological niche in the DPN nutraceutical landscape because its three primary mechanisms address three cellular compartments — Schwann cells, DRG satellite glia, and DRG neurons — through three fundamentally different molecular actions: PCSK9 inhibition for cholesterol supply restoration, STING palmitoylation blockade for innate immune silencing, and NIX-LC3B enhancement for receptor-mediated mitophagy. These are not variations on a common theme (antioxidant, anti-inflammatory) but genuinely distinct pharmacological strategies, each targeting a different rate-limiting step in a different cell type within the complex cellular ecology of the diabetic peripheral nerve.

The mechanistic complementarity between Mechanisms 2 and 3 — where enhanced mitophagy reduces the mtDNA leakage that drives STING activation — suggests that myricetin’s therapeutic effects may be self-reinforcing in ways that are difficult to capture in single-endpoint preclinical studies. This mechanistic synergy is an argument for viewing myricetin’s DPN benefits as greater than the sum of its individual mechanism contributions when assessed in isolation.

From a clinical practice standpoint, patients with confirmed DPN who are interested in dietary and nutraceutical strategies can reasonably incorporate myricetin through increased consumption of bilberries, cranberries, and red wine (in moderation, in consultation with their diabetes care team), and through standardized bilberry extract or isolated myricetin supplements at 200–400 mg/day with food. These approaches should be pursued as complements to — never replacements for — optimal glycemic control, prescribed DPN medications, and regular podiatric monitoring for foot complications. The promise of myricetin in DPN is genuinely distinct from earlier-generation antioxidant trials, because its molecular targets are specific cellular mechanisms rather than generic oxidative damage — but that promise will require prospective clinical trial confirmation before it translates into evidence-based prescriptive recommendations.

Sources and Further Reading

• Sahebkar A, et al. “Effect of plant extracts and phytochemicals on plasma PCSK9 concentrations: a systematic review and meta-analysis of randomized controlled trials.” Curr Med Chem. 2019;26(20):3691-3706.
• Borén J, et al. “LDL-cholesterol versus apolipoprotein B in familial hypercholesterolaemia: implications for therapy and clinical management.” Eur Heart J. 2020;41(24):2266-2273.
• Dogan MF, et al. “Myricetin protects against streptozotocin-induced diabetic neuropathy by inhibiting oxidative stress and inflammation.” Mol Cell Biochem. 2021;476(1):463-476.
• Cai Z, et al. “The cGAS-STING signaling pathway: a molecular link between immunity and metabolism.” Front Immunol. 2023;14:1173808.
• Chin EN, et al. “Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic.” Science. 2020;369(6506):993-999.
• Hansen M, et al. “Mitophagy in physiological and pathological conditions.” Cell Mol Life Sci. 2021;78(12):4863-4888.
• Rogov V, et al. “Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy.” Mol Cell. 2014;53(2):167-178.
• Schweers RL, et al. “NIX is required for programmed mitochondrial clearance during reticulocyte maturation.” Proc Natl Acad Sci USA. 2007;104(49):19500-19505.
• Wang Y, et al. “Myricetin alleviates diabetic peripheral neuropathy by inhibiting neuroinflammation and maintaining mitochondrial integrity.” J Neuroinflammation. 2022;19(1):87.
• Li R, et al. “Myricetin as a potential inhibitor of PCSK9 expression: a molecular docking and in vitro study.” Biomed Pharmacother. 2023;164:114975.
• Pop-Busui R, et al. “Diabetic neuropathy: a position statement by the American Diabetes Association.” Diabetes Care. 2017;40(1):136-154.
• Huxley RR, et al. “Dietary intake of flavonoids and isoflavones and risk of ischemic stroke.” Am J Epidemiol. 2011;173(8):857-866.
• Leifert WR, Abeywardena MY. “Cardioprotective actions of grape polyphenols.” Nutr Res. 2008;28(11):729-737.
• Cho YS, et al. “Myricetin exhibits antidiabetic and antihyperlipidemic activities and improves antioxidant status in type 2 diabetic db/db mice.” Evid Based Complement Alternat Med. 2012;2012:712629.

Related Articles

• Insulin Resistance: Symptoms, Causes & Reversal
• Leaky Gut & Intestinal Permeability Protocol
• Magnesium Deficiency: Symptoms & Solutions

Related Compounds

• Icariin & Diabetic Neuropathy
• Baicalein & Diabetic Neuropathy
• Kaempferol & Diabetic Neuropathy
• Naringenin & Diabetic Neuropathy